Global Genital Herpes Treatment Market - 2024-2031

Global Genital Herpes Treatment Market - 2024-2031

The global genital herpes treatment market reached US$ 1,143.19 million in 2023 and is expected to reach US$ 1,669.81 million by 2031, growing at a CAGR of 4.8% during the forecast period 2024-2031.

Genital herpes is a sexually transmitted disease (STD) caused by the herpes simplex virus (HSV) especially HSV type 2. It can cause sores in the genital or rectal area, buttocks, and thighs. The infection transmits through sexual contact with the infected person. The complications of genital herpes are easy contraction of other STIs, newborn infections, internal inflammatory disease, eye infection, and rarely swelling of brain and infection in the internal organs. There is currently no cure for genital herpes, the mainstay of treatment includes antiviral drugs such as acyclovir, famciclovir, valacyclovir and penciclovir.

Market Dynamics: Drivers

Rising research and development activities and pipeline products

Currently, the U.S. Food and Drug Administration (FDA) has approved only a limited number of drugs for the treatment of genital herpes. These drugs include acyclovir, famciclovir, valacyclovir, and penciclovir, the commonly used antiviral drugs. Despite the rising prevalence of the condition, the therapeutic options are limited creating a demand for novel drugs. Several manufacturers have been investing in and developing novel drugs that specifically aim for genital herpes. These drugs, if entered into the market, may create a huge impact on the market dynamics.

For instance, AiCuris Anti-infective Cures AG has been developing Pritelivir a novel anti-viral drug for the treatment of genital herpes in immunocompromised subjects with acyclovir-resistant or acyclovir-susceptible mucocutaneous HSV infection. The drug is currently in an investigational phase 3 study and is anticipated to finish the trial by the mid of 2025.

GSK plc. Has been developing a novel recombinant protein GSK3943104 for the suppression of recurrent genital herpes in adults aged 18 years and older. The novel product is currently in phase 2 clinical trial which is anticipated to be finished by mid of 2026.

Moderna, Inc. has been investigating a novel mRNA vaccine mRNA-1608 in healthy adults 18 to 55 years of age with recurrent HSV-2 genital herpes. The investigational vaccine is currently in phase 1/2 clinical trial and is estimated to be finished by mid of 2025.

Moreover, BioNTech SE has been investigating BNT163 in a phase 1 clinical trial to prevent genital herpes. BNT163 is an anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as an intramuscular injection. The study is anticipated to be finished by the end of 2025.

In addition, the rising prevalence of genital herpes, rising government initiatives to increase the awareness are expected to further propel the market growth in the forecast period.

Restraints

The social stigma surrounding sexually transmitted diseases (STDs), such as genital herpes, significantly hinders the growth of the treatment market. Stigma leads to underreporting and misdiagnosis, delayed diagnosis, limited public awareness, and reduced testing volume which ultimately reduce the number of patients opting for treatment. Moreover, the asymptomatic nature of the conditions in some patients may limit the patient population opting for treatment.

For more details on this report - Request for Sample

Segment Analysis

The global genital herpes treatment market is segmented based on type, drug type, route of administration, distribution channel, and region.

The acyclovir in the drug type segment accounted for approximately 56.6% of the global genital herpes treatment market share

Acyclovir, a long-standing antiviral medication, has proven effective in treating genital herpes, reducing outbreak severity and duration. Its safety profile and efficacy have been extensively studied, making it a trusted treatment option. Acyclovir is available in multiple formulations, including oral tablets, topical creams, and intravenous formulations, making it versatile, and suitable for treating a variety of patients. Moreover, the drug is manufactured by many well-known pharmaceutical companies and is available globally.

It is recommended as a first-line treatment for genital herpes due to its effectiveness, tolerability, and established safety profile. According to the World Health Organization (WHO) STI guidelines, For adults and adolescents with a first clinical episode of genital HSV infection, the preferred drug is a standard dose of aciclovir over valaciclovir or famciclovir. In addition, acyclovir is also used in suppressive therapy to reduce outbreak frequency, making it suitable for individuals with recurrent genital herpes.

Geographical Analysis

North America has a significant market share of 43.3% in the global genital herpes treatment market.

The prevalence of genital herpes is highest in the North American region, especially in the U.S. which is a strong contributor of the regions market dominance. For instance, as per a cohort study conducted in the U.S. from 2019 to 2021, published in the Journal of the American Sexually Transmitted Diseases Association (ASTDA), the standardized prevalence of diagnosed genital herpes and recurrent genital herpes ranged from 236 to 280 cases per 100,000 person-years and 81 to 98 cases per 100,000 person-years, respectively. As per DataM estimates, the prevalent cases of genital herpes in the U.S. from 2019 to 2023 are as follows.



Moreover, the region is well known for its advanced healthcare infrastructure. The patients have access to care with ease, and the healthcare facilities provide a plethora of treatment options. Moreover, the availability of drugs both in branded and generic forms provides affordable options to patients in the region. In addition, the awareness campaigns by health agencies, government bodies, and NGOs in the region, create a huge impact on society which results in higher treatment rates as compared to any other region.

Market Segmentation

By Type
• HSV-1 Genital Herpes
• HSV-2 Genital Herpes

By Drug Type
• Acyclovir
• Valacyclovir
• Famciclovir
• Others

By Route of Administration
• Oral
• Parenteral
• Topical
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major players in the genital herpes treatment market include Bausch Health Companies Inc., LNHC, Inc., GSK plc., Camber Pharmaceuticals, Inc., Rising Pharma Holdings, Inc., Teva Pharmaceuticals USA, Inc., Padagis, Viatris Inc., AdvaCare Pharma, and Sun Pharmaceutical Industries Ltd. among others.

Why Purchase the Report?
• To visualize the global genital herpes treatment market segmentation based on type, drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of genital herpes treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global genital herpes treatment market report would provide approximately 70 tables,63 figures, and 187 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies